Valneva (VALN) Competitors $5.75 +0.10 (+1.77%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends VALN vs. IMCR, NTLA, SNDX, CNTA, RCKT, RXRX, TARS, RCUS, SPRY, and SYREShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Immunocore (IMCR), Intellia Therapeutics (NTLA), Syndax Pharmaceuticals (SNDX), Centessa Pharmaceuticals (CNTA), Rocket Pharmaceuticals (RCKT), Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Arcus Biosciences (RCUS), ARS Pharmaceuticals (SPRY), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Immunocore Intellia Therapeutics Syndax Pharmaceuticals Centessa Pharmaceuticals Rocket Pharmaceuticals Recursion Pharmaceuticals Tarsus Pharmaceuticals Arcus Biosciences ARS Pharmaceuticals Spyre Therapeutics Immunocore (NASDAQ:IMCR) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends. Do institutionals & insiders have more ownership in IMCR or VALN? 84.5% of Immunocore shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 9.1% of Immunocore shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, IMCR or VALN? Immunocore has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Valneva has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Do analysts recommend IMCR or VALN? Immunocore presently has a consensus target price of $74.36, suggesting a potential upside of 134.59%. Valneva has a consensus target price of $18.50, suggesting a potential upside of 221.74%. Given Valneva's stronger consensus rating and higher probable upside, analysts clearly believe Valneva is more favorable than Immunocore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunocore 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to IMCR or VALN? In the previous week, Immunocore had 2 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Immunocore and 0 mentions for Valneva. Immunocore's average media sentiment score of 0.15 beat Valneva's score of 0.00 indicating that Immunocore is being referred to more favorably in the media. Company Overall Sentiment Immunocore Neutral Valneva Neutral Is IMCR or VALN more profitable? Immunocore has a net margin of -19.16% compared to Valneva's net margin of -21.31%. Immunocore's return on equity of -14.68% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets Immunocore-19.16% -14.68% -6.68% Valneva -21.31%-20.01%-6.58% Which has stronger earnings & valuation, IMCR or VALN? Immunocore has higher revenue and earnings than Valneva. Immunocore is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunocore$249.43M6.36-$55.29M-$1.08-29.35Valneva$165.52M2.82-$109.78M-$0.52-11.06 Does the MarketBeat Community believe in IMCR or VALN? Immunocore received 31 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 74.12% of users gave Immunocore an outperform vote while only 60.38% of users gave Valneva an outperform vote. CompanyUnderperformOutperformImmunocoreOutperform Votes6374.12% Underperform Votes2225.88% ValnevaOutperform Votes3260.38% Underperform Votes2139.62% SummaryImmunocore beats Valneva on 11 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$467.19M$3.14B$5.39B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-11.0612.18113.8115.12Price / Sales2.82332.371,483.2593.03Price / CashN/A148.6339.6434.05Price / Book2.884.024.665.02Net Income-$109.78M-$42.25M$119.06M$225.46M7 Day Performance-3.20%8.08%0.79%0.37%1 Month Performance0.70%8.72%5.65%3.57%1 Year Performance-51.00%32.11%36.76%29.42% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva1.54 of 5 stars$5.75+1.8%$18.50+221.7%-50.6%$467.19M$165.52M-11.06700Gap UpHigh Trading VolumeIMCRImmunocore2.2403 of 5 stars$32.80+0.9%$75.17+129.2%-30.1%$1.64B$280.91M-30.37497Upcoming EarningsNTLAIntellia Therapeutics4.2677 of 5 stars$15.95+0.6%$59.13+270.7%-41.9%$1.62B$36.28M-2.91600High Trading VolumeSNDXSyndax Pharmaceuticals4.0313 of 5 stars$18.75-1.3%$35.90+91.5%+36.4%$1.59B$3.50M-5.55110Upcoming EarningsCNTACentessa Pharmaceuticals3.456 of 5 stars$15.50flat$25.17+62.4%+128.8%$1.56B$6.85M-9.9472RCKTRocket Pharmaceuticals4.3151 of 5 stars$17.04-1.0%$51.75+203.7%-10.6%$1.55BN/A-6.11240Upcoming EarningsRXRXRecursion Pharmaceuticals2.9092 of 5 stars$6.48+1.9%$9.40+45.1%+25.7%$1.54B$48.62M-4.00400Upcoming EarningsTARSTarsus Pharmaceuticals0.7604 of 5 stars$39.41+1.3%$51.60+30.9%+226.0%$1.49B$83.37M-8.8050Positive NewsRCUSArcus Biosciences2.7196 of 5 stars$16.32-8.5%$33.67+106.3%-2.0%$1.48B$247M-5.28500Upcoming EarningsSPRYARS Pharmaceuticals2.8441 of 5 stars$14.77-4.1%$24.00+62.5%+328.7%$1.43B$500,000.00-31.4390SYRESpyre Therapeutics2.7206 of 5 stars$34.81+3.3%$46.43+33.4%N/A$1.40B$890,000.00-2.25100Positive NewsGap Up Related Companies and Tools Related Companies IMCR Alternatives NTLA Alternatives SNDX Alternatives CNTA Alternatives RCKT Alternatives RXRX Alternatives TARS Alternatives RCUS Alternatives SPRY Alternatives SYRE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VALN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
